MARINUS PHARMACEUTICALS, INC.: Nasdaq/NYSE listing notice — Marinus Pharma receives Nasdaq bid price and market value deficiency notices

MARINUS PHARMACEUTICALS, INC.

Nasdaq notified MRNS that bid price closed below $1.00 for 30 consecutive days.
Company has until June 4, 2025 to regain compliance for a minimum 10 consecutive days.
Also notified that market value of listed securities remained below $50 million for 30 days.
Company may consider options to regain compliance but no assurance of success.
Failure to comply may result in delisting; company could appeal or transfer to Capital Market.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

MARINUS PHARMACEUTICALS, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5450(a)(1)

Exact text from the filing

December 6, 2024, Marinus Pharmaceuticals, Inc. (the “Company”) received written notice (the “Bid Price Deficiency Notice”) from The Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that for the previous 30 consecutive business days, the bid price for the Company’s common stock, par value $0.001 (the “Common Stock”), had closed below the $1.00 per share minimum bid price requirement for continued listing on The Nasdaq Global Market, as set forth in Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”). The Bid Price Deficiency Notice has no effect at this time on the li

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001558370-24-016118

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.